[go: up one dir, main page]

MX2021014161A - Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. - Google Patents

Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.

Info

Publication number
MX2021014161A
MX2021014161A MX2021014161A MX2021014161A MX2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A
Authority
MX
Mexico
Prior art keywords
syndrome
methods
sjã
gren
bruton
Prior art date
Application number
MX2021014161A
Other languages
English (en)
Inventor
Martin Kaul
Bruno Bieth
Buck Stefan De
Souvik Bhattacharya
Maciej Cabanski
Bruno Cenni
Arvind Kinhikar
Andrijana Radivojevic
Garami Alessandra Vitaliti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021014161A publication Critical patent/MX2021014161A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se relaciona con métodos para el tratamiento de la enfermedad de Síndrome de Sjögren utilizando un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo. También se divulga en la presente un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo, para el tratamiento de pacientes con Síndrome de Sjögren, así como también medicamentos, regímenes de dosificación, formulaciones farmacéuticas, formas de dosificación, y kits para utilizar en los usos y métodos divulgados.
MX2021014161A 2019-05-23 2020-05-20 Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. MX2021014161A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851994P 2019-05-23 2019-05-23
PCT/IB2020/054754 WO2020234781A1 (en) 2019-05-23 2020-05-20 Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2021014161A true MX2021014161A (es) 2022-01-04

Family

ID=70918750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014161A MX2021014161A (es) 2019-05-23 2020-05-20 Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.

Country Status (23)

Country Link
US (2) US12383556B2 (es)
EP (2) EP3972603B1 (es)
JP (2) JP7765970B2 (es)
KR (1) KR20220011652A (es)
CN (1) CN113811301A (es)
AU (2) AU2020278236B2 (es)
BR (1) BR112021023110A2 (es)
CA (1) CA3137271A1 (es)
CL (1) CL2021003034A1 (es)
DK (1) DK3972603T3 (es)
ES (1) ES3004516T3 (es)
FI (1) FI3972603T3 (es)
HR (1) HRP20241584T1 (es)
HU (1) HUE069020T2 (es)
IL (1) IL287745B2 (es)
LT (1) LT3972603T (es)
MX (1) MX2021014161A (es)
PL (1) PL3972603T3 (es)
PT (1) PT3972603T (es)
RS (1) RS66195B1 (es)
SI (1) SI3972603T1 (es)
TW (1) TWI857060B (es)
WO (1) WO2020234781A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020278236B2 (en) 2019-05-23 2025-08-07 Novartis Ag Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
US20250281413A1 (en) * 2021-01-26 2025-09-11 Novartis Ag Pharmaceutical composition
JP7564347B2 (ja) 2021-09-03 2024-10-08 ノバルティス アーゲー 多発性硬化症を治療するためのｌｏｕ０６４
EP4448114A1 (en) 2021-12-14 2024-10-23 Novartis AG Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
KR102875105B1 (ko) 2023-04-03 2025-10-21 주식회사 사이알바이오 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036741A1 (es) 2001-10-05 2004-09-29 Combinatorx Inc Combinaciones para el tratamiento de los trastornos inmunoinflamatorios
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
ES2897910T3 (es) * 2015-12-16 2022-03-03 Boehringer Ingelheim Int Derivados bipirazolilo útiles para el tratamiento de enfermedades autoinmunitarias
WO2017123695A1 (en) * 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
WO2019046292A1 (en) 2017-08-28 2019-03-07 Spectrix Therapeutics, LLC COMPOUND FOR TREATING SJÖGREN SYNDROME
CA3076872A1 (en) 2017-11-03 2019-05-09 Novartis Ag Anti-cd40 antibodies for use in treatment of sjogren's syndrome
TWI694995B (zh) * 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
AU2020278236B2 (en) 2019-05-23 2025-08-07 Novartis Ag Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
AU2020278236B2 (en) 2025-08-07
DK3972603T3 (da) 2024-12-02
SI3972603T1 (sl) 2025-02-28
PL3972603T3 (pl) 2025-02-03
EP4442321A2 (en) 2024-10-09
EP3972603A1 (en) 2022-03-30
IL287745B1 (en) 2025-10-01
LT3972603T (lt) 2024-12-10
TWI857060B (zh) 2024-10-01
AU2020278236A1 (en) 2022-01-06
IL287745B2 (en) 2026-02-01
CA3137271A1 (en) 2020-11-26
BR112021023110A2 (pt) 2022-04-12
CN113811301A (zh) 2021-12-17
HRP20241584T1 (hr) 2025-01-31
HUE069020T2 (hu) 2025-02-28
WO2020234781A1 (en) 2020-11-26
ES3004516T3 (en) 2025-03-12
US12383556B2 (en) 2025-08-12
JP2025165957A (ja) 2025-11-05
US20250339428A1 (en) 2025-11-06
JP7765970B2 (ja) 2025-11-07
TW202110451A (zh) 2021-03-16
IL287745A (en) 2021-12-01
KR20220011652A (ko) 2022-01-28
US20220175772A1 (en) 2022-06-09
CL2021003034A1 (es) 2022-09-09
EP4442321A3 (en) 2025-01-01
AU2025263830A1 (en) 2025-11-27
RS66195B1 (sr) 2024-12-31
FI3972603T3 (fi) 2024-12-04
AU2020278236A8 (en) 2022-04-28
JP2022533968A (ja) 2022-07-27
EP3972603B1 (en) 2024-09-04
PT3972603T (pt) 2024-11-26

Similar Documents

Publication Publication Date Title
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
MX2019012884A (es) Terapia de combinacion.
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
MX2018016330A (es) Combinaciones para tratamiento del cáncer.
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
MX2020005518A (es) Mezclas no racemicas y usos de las mismas.
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
MX2023000812A (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CO2022008606A2 (es) Derivados de piridopirimidinona como antagonistas de ahr
AR104068A1 (es) Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
MX2019011620A (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
AR131601A1 (es) MÉTODOS PARA TRATAR EL SÍNDROME DE SJÖGREN PRIMARIO MEDIANTE EL USO DE ANTAGONISTAS DE FcRn
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
CO2022008001A2 (es) Métodos para el tratamiento de trastornos depresivos
EA202190360A1 (ru) Комбинированная терапия
MX2024010392A (es) Remibrutinib para el uso en el tratamiento de hidradenitis supurativa.
ZA202305383B (en) Topical administration of 2- (diethylamino) ethyl 2- (4-isobutylphenyl) propionate for treatment of diseases
MX2022001227A (es) Metodos de tratamiento del cancer multifocal.